Please login to the form below

Not currently logged in
Email:
Password:

selumetinib

This page shows the latest selumetinib news and features for those working in and with pharma, biotech and healthcare.

AZ to address Imfinzi setback, but sees potential with Tagrisso

AZ to address Imfinzi setback, but sees potential with Tagrisso

Meanwhile, AZ has plans to expand the use of its biggest selling oncology asset Tagrisso, after it announced that is being tested with potential new medicines savolitinib or selumetinib in NSCLC

Latest news

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    But now hopes are high for two late-stage drugs: olaparib and selumetinib. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics